Skip to main content
SpringerLink
Log in

Lamivudine for chronic hepatitis B

  • New drugs and disease management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Jarvis B, Faulds D. Lamivudine: a review of its therapeutic potential in chronic hepatitis B. Drugs 1999 Jul; 58(1): 101–41

    Article  PubMed  CAS  Google Scholar 

  2. Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997; 336: 347–56

    Article  PubMed  CAS  Google Scholar 

  3. Malik AH, Lee WM. Hepatitis B therapy: the plot thickens. Hepatology 1999; 30: 579–81

    Article  PubMed  CAS  Google Scholar 

  4. Lok ASF, Ghany MG, Watson G, et al. Predictive value of amino-transferase and hepatitis B virus DNA levels on response to interferon therapy for chronic hepatitis B. J Viral Hepatit 1998; 5: 171–8

    Article  CAS  Google Scholar 

  5. Lai C-L, Chien R-N, Leun NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med 1998; 339: 61–8

    Article  PubMed  CAS  Google Scholar 

  6. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341: 1256–63

    Article  PubMed  CAS  Google Scholar 

  7. Di Marco V, Lo Iacono O, Camma C, et al. The long-term course of chronic hepatitis B. Hepatology 1999; 30: 257–64

    Article  PubMed  Google Scholar 

  8. Dienstag JL, Schiff ER, Mitchell M, et al. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy. Hepatology 1999; 30: 1082–7

    Article  PubMed  CAS  Google Scholar 

  9. Chien R-N, Liaw Y-F, Atkins M. Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology 1999; 30: 770–4

    Article  PubMed  CAS  Google Scholar 

  10. Tassopoulos NC, Volpes R, Pastore G, et al. Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 1999; 29: 889–96

    Article  PubMed  CAS  Google Scholar 

  11. Liaw Y-F, Chien R-N, Yeh C-T et al. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567–72

    Article  PubMed  CAS  Google Scholar 

  12. Farrell GC. Immunosuppression and reactivation of hepatitis B in the lamivudine era: opportunities for prevention and exploitation? J Gastroenterol Hepatol 1999; 14: 741–4

    Article  PubMed  CAS  Google Scholar 

  13. Pianko S, McHutchison J. Chronic hepatitis B: new therapies on the horizon? Lancet 1999 Nov 13; 354: 1662–3

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lamivudine for chronic hepatitis B. Drugs Ther. Perspect 15, 1–5 (2000). https://doi.org/10.2165/00042310-200015040-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00042310-200015040-00001

Keywords

Search

Navigation